Clene Inc - Warrants (30/12/2025)
CLNNW
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.2M
Close$
$-2.59
144161.1% downside
Current Fair Value
144161.1% downsideOvervalued by 144161.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $55.20 Million |
|---|---|
| Enterprise Value | $67.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.65 |
| Beta | 0.79 |
| Outstanding Shares | 12,382,702 |
Return
| Return on Equity | 159.49% |
|---|---|
| Return on Assets | -171.51% |
| Return on Invested Capital | -118.16% |
Valuation & Multiples
| P/E Ratio | -1.22 |
|---|---|
| PEG | -1.5 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 344.54 |
| Enterprise Value to EBIT | -3.16 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | -0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Clene Inc
2,021 employeesClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally a...